INSM catalysts and FDA events, page 2.
Updated Snapshot 20261116T222116ZBuilt
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on INSM PDUFA dates and upcoming catalysts. This page continues the list.
Past catalysts and FDA decisions (continued)
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| June 10, 2025 | — | INSM | Topline readout | pulmonary arterial hypertension | Positive | sec_424b |
| Jun 2025Month disclosed | INS1201 | INSM | Topline readout | PAH Completed | Positive | SEC 8-K Exhibit 99.1 |
| May 8, 2025 | — | INSM | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| mid-2025Half-year disclosed | INS1201 | INSM | Topline readout | PAH Completed in December 2024 | Scheduled | SEC 8-K Exhibit 99.1 |
| February 18, 2025 | — | INSM | Earnings | — | Completed | SEC 8-K Exhibit 99.1 |
| February 6, 2025 | BRINSUPRI® (brensocatib) | INSM | NDA/BLA accepted | bronchiectasis | Completed | SEC Form 8-K |
| Q1 2025Quarter disclosed | BRINSUPRI® (brensocatib) | INSM | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Dec 2024Month disclosed | BRINSUPRI® (brensocatib) | INSM | Trial start | — | Completed | SEC Form 10-Q |
| Dec 2024Month disclosed | BRINSUPRI® (brensocatib) | INSM | NDA/BLA submission | bronchiectasis with the U | Completed | SEC 8-K Exhibit 99.1 |
| May 2024Month disclosed | — | INSM | Topline readout | — | Positive | SEC Form 10-Q |
| Mar 2024Month disclosed | XHANCE | INSM | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| Sep 2023Month disclosed | azithromycin | INSM | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| October 19, 2020 | Arikayce Kit (amikacin sulfate) | INSM | Label expansion | — | Approved | openFDA Drugs@FDA |
| September 28, 2018 | Arikayce Kit (amikacin sulfate) | INSM | FDA approval | — | Approved | openFDA Drugs@FDA |
Every catalyst is quoted from INSM’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.